RecruitingNCT06234306

Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

Sponsor

Copenhagen University Hospital at Herlev

Enrollment

500 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Small-bowel Adenocarcinoma

Summary

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with small-bowel adenocarcinoma. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.